Effects of patient age and physician training on choice and dose of benzodiazepine hypnotic drugs.

We conducted a cross-sectional review of all prescriptions (N = 554) for triazolam and flurazepam hydrochloride written by nonpsychiatrists to outpatients at a university affiliated Veterans Administration hospital. We sought to determine whether triazolam, an agent with a short half-life, was used preferentially in older patients (age greater than or equal to 70 years). We also wanted to determine whether dosages of triazolam or flurazepam were lowered in elderly patients. Our findings showed that prescriber level of training was a much stronger determinant of drug choice than patient age. Attending physicians prescribed flurazepam twice as often as interns. Lower dosages of both agents were prescribed more frequently to older patients. Our data suggest that some physicians choose a benzodiazepine hypnotic out of habit rather than application of pharmacologic principles, but reduce doses appropriately when prescribing to elderly patients.

Influence of age and body weight on spine and femur bone mineral density in U.S. white men.

Bone mineral density (BMD) was measured in normal white males using 153 Gd dual-photon absorptiometry. Measurements were made on the lumbar spine (n = 315) and on the proximal femur (n = 282) utilizing three regions of interest. There was a small but significant age-related decrease in spinal BMD (r = -0.11; -0.001 g/cm2 per year) and trochanteric BMD (r = 0.27; -0.002 g/cm2 per year). The BMD of the other femoral sites decreased more rapidly; the femoral neck (r = -0.58; -0.005 g/cm2 per year) and Ward's triangle (r = -0.69; -0.007 g/cm2 per year) declined by about 21 and 34%, respectively, from age 20 to age 70. These femoral BMD decreases were three to four times greater than those usually seen in the peripheral skeleton in males but less than the decreases of 25-30 and 40% in the femoral neck and Ward's triangle of white females. This pattern of aging bone loss may partially explain the paucity of spine fractures and the lower incidence of hip fractures in males versus females.

Diagnosis and treatment of outpatient insomnia by psychiatric and nonpsychiatric physicians.

Insomnia is commonly encountered in general medical practice, but little is known about how primary care physicians manage this problem. We reviewed medical records describing 536 patient encounters in which either triazolam (Halcion) or flurazepam (Dalmane) was prescribed for outpatient use. Only 12% of the progress notes written by internists or surgeons contained even a remote reference to sleep, whereas 74% of psychiatrist's notes contained at least some sleep symptom documentation. In a multivariate analysis including the number of medical and psychiatric diagnoses, patient age, and physician gender, only the prescriber department was independently associated with the presence of symptom documentation. We also found that 30% of the prescriptions written by internists or surgeons were for inappropriately large quantities of these drugs (180 or more doses) compared with 6% of the prescriptions written by psychiatrists. We conclude that the evaluation of insomnia by nonpsychiatrists is often incomplete and that hypnotic drugs may be inappropriately prescribed by these physicians. Further efforts are needed to improve the management of insomnia by primary care physicians in the outpatient setting.

Failure to limit quantities of benzodiazepine hypnotic drugs for outpatients: placing the elderly at risk.

PURPOSE: The long-term use of benzodiazepine hypnotics by the elderly is associated with serious side effects, and prescriptions of large quantities of these agents allow such use. Therefore, we determined the quantities of these agents prescribed to outpatients in our Veterans Administration teaching hospital, and the relationship of patient age to total number of doses prescribed per prescription. PATIENTS AND METHODS: Pharmacy and patient records related to 655 consecutive prescriptions for triazolam (Halcion) and flurazepam (Dalmane) were reviewed. Only 266 (41%) of the prescriptions were for 30 or fewer doses, while 178 (27%) were written for 180 or more doses. RESULTS: Thirty-six percent of prescriptions for patients aged 65 years or older were for 180 or more doses, compared with 24% for those aged 45 to 64 years old, and 16% of the prescriptions for patients less than 45 years old (p less than 0.0001). In a multivariate analysis controlling for six other factors related to the total number of doses prescribed, patients aged 65 years or older were still more likely to receive a prescription for 180 or more doses (relative risk 1.9, 95% confidence interval 1.3, 2.8). CONCLUSION: We conclude that inappropriately large quantities of benzodiazepine hypnotics were commonly prescribed, and that patients aged 65 years or older were at greatest risk for receiving such prescriptions.

An examination of histamine-2 receptor antagonist use by Medicaid recipients in Wisconsin long-term care facilities.

The Wisconsin Drug Utilization Review Project used Medicaid claims data to examine the use of long-term, full doses histamine-2 receptor antagonists (H2RAs) among long-term care facility (LTCF) residents, ie, doses exceeding 800 mg per day of cimetidine or 150 mg per day of ranitidine for 12 weeks or more. Additional information about a small but representative sample of patients was obtained from consultant pharmacists by mail questionnaire. Of approximately 35,000 residents, there were 1,046 receiving long-term, full-dose H2RAs during 1984 at a cost of +405,848. No differences were noted between treated patients and the overall LTCF population by gender, age, level of care, or geographic locality. Among 387 patients receiving therapy for the last 3 months of 1984, over one half received antacids and over 20% received nonsteroidal anti-inflammatory drugs concurrently. According to survey respondents, almost one half of the patients had no diagnosis amenable to treatment by H2RAs. Diagnostic procedures conducted within 30 days prior to the initiation of H2RAs were hemoglobin/hematocrit assessment (performed on 53% of patients), stool testing (34%), radiological exam (23%) and endoscopy (8%). The results suggest that there is widespread use of long-term full-dose H2RAs in LTCFs for undocumented, inappropriate, and poorly supported diagnoses. Such findings are of concern to all persons charged with monitoring drug use in nursing homes because of the implications for both quality and cost of care. Information from this study will be used in designing a program to reduce inappropriate utilization of H2RAs, and Medicaid claims data will be used to monitor trends in utilization.

Effects of chronic medical illness and dementia on the dexamethasone suppression test.

The dexamethasone suppression test (DST) was performed on 26 elderly male outpatients in a geriatric medical clinic. Patients with depression were excluded. All patients had two or more medical diagnoses. Fourteen patients also met DSM-III criteria for dementia. No patient had an abnormal DST result. The authors suggest that neither chronic medical illness nor dementia causes false-positive DST results in this patient population in an outpatient setting, and discuss the findings in relation to previous reports.

The dexamethasone suppression test in demented outpatients with and without depression.

The dexamethasone suppression test (DST) was given to 33 elderly, male outpatients, previously diagnosed by DSM-III criteria as having dementia. Fifteen of these patients also had signs and symptoms of depression and, except for the presence of organic mental syndrome, would have met DSM-III criteria for major depressive episode. Of these 15 depressed, demented patients, 40% had abnormal DST results. None of the 18 patients who had dementia alone had abnormal DSTs. Our data suggest that in elderly, demented outpatients, an abnormal DST may be associated with concomitant depression.

Variation in light transmission properties of amber oral syringes.

Four brands of amber oral syringes were tested for compliance with compendial standards for light-resistant packaging. United States Pharmacopoeia (USP) specifications state that light-resistant packaging must not transmit more than 10% of incident light with wavelengths of 290-450 nm. The amount of light transmitted by samples of the barrels of 200 amber plastic oral syringes from each of four manufacturers was determined by spectrophotometry. Samples of both the printed and unprinted sides of the barrel were tested (after removal of all ink). The thickness of each syringe-barrel sample was measured, and the apparent density was determined. All of the Becton-Dickinson syringes tested met the USP standard for light transmittance, and none of the syringes from Baxa or Solopak met the compendial standards. Of the Burron syringes tested, 70 syringes met the standard, 83 did not meet the standard, and 47 could not be classified. The samples of the printed side of the syringe barrel had light transmission properties similar to those of the unprinted side with the exception of the syringes from Baxa, which had substantially higher apparent densities at all wavelengths for the printed side. Only one manufacturer's oral syringes consistently met the USP standard for light-resistant packaging. Further testing is needed to determine the clinical importance of these findings.

Pathogenesis and management of primary osteoporosis.

The pathophysiology of primary osteoporosis and the various therapeutic regimens that have been used are reviewed. Osteoporosis is a major public health problem because the incidence of hip, wrist, and vertebral fractures associated with bone loss is high. Postmenopausal women are at increased risk for developing osteoporosis because bone mineral content is lower in women than in men, dietary calcium intake is frequently insufficient, intestinal absorption of calcium decreases with age, and the rate of bone loss accelerates at menopause. The efficacy of many single and combination therapies in preventing or treating osteoporosis has been studied. Differences in study design and diagnostic techniques and the heterogeneous nature of osteoporosis make evaluation of clinical trials difficult. Exercise helps to maintain skeletal mass, but amenorrhea caused by vigorous activity may be harmful. The efficacy of estrogen replacement therapy is documented best; many studies have shown that estrogens slow the rate of bone loss and reduce the incidence of fractures, but the association of estrogen use with endometrial cancer and breast cancer is of concern. Progesterones may protect against endometrial cancer, but undesirable effects of oral contraceptives have resulted in a hesitancy to use combination hormonal therapy. All adults should meet daily nutritional requirements for calcium, but this intake may be insufficient for elderly persons and is below recommended doses for treating osteoporosis. A daily intake of at least 1000-1500 mg of elemental calcium has been shown to slow the rate of bone loss. Nutritional requirements for vitamin D should be met, but benefits from pharmacologic doses have not been demonstrated. The role of fluoride, calcitonin, anabolic steroids, and vitamin D metabolites is unclear. Fluoride has the potential to increase bone mass, but effects on bone histology and fracture rates require further study. The major goals for the management of osteoporosis are maintenance of bone mass and prevention of fractures. An adequate intake of calcium and regular weight-bearing exercise are important preventive measures. Despite the documented effectiveness of estrogens, risks associated with long-term use are of concern.

Atraumatic vertebral deformities in elderly males.

Little information is available on the prevalence of vertebral wedge deformities in elderly males; therefore, 116 ambulatory male volunteers age 65 and over were studied with lumbar and thoracic radiographs. Each patient was questioned concerning a history of high-energy spinal trauma. Those having 25% or greater anterior vertebral wedging were identified. Eleven percent of the males had at least one 25% atraumatic wedge deformity, and 2% had two or more such vertebra. These results are discussed in relation to the few published studies on this topic.

Lack of correlation between aortic calcification and bone density.

Previous radiographic studies have suggested a positive relationship between two degenerative processes associated with aging: calcification of the abdominal aorta and osteoporosis. Such a relationship has not been studied using modern quantitative densitometry. Aortic calcification was quantified on spinal radiographs from 112 elderly men. Bone mineral density was determined at six scanning sites using photon densitometry. There was no significant correlation between aortic calcification and bone mineral density at any of the scanning sites when the effect of age was held constant in the statistical analysis.

The effect of overlying calcification on lumbar bone densitometry.

We studied bone mineral density (BMD) of the spine using dual photon absorptiometry, as well as standard anterior-posterior and lateral lumbar spine X-ray film in 113 ambulatory elderly male volunteers with a mean age of 72 years (range 66-91 years). Each subject had three measurements taken for lumbar vertebrae 1 through 4: BMD, length of aortic calcification (AC), and degenerative facet sclerosis graded 0-3. A separate statistical model was fit to BMD for each vertebra using analysis of covariance. AC did not contribute significantly to BMD. BMD was increased by 0.28-0.03 g/cm2 (L1-L4) with a sclerosis score of 2, and by 0.47-0.25 g/cm2 with a sclerosis score of 3, P less than 0.001. The association between increased BMD and overlying facet sclerosis may be related to the bone density within the sclerosis itself or to an association between degenerative joint disease and a generalized increase in subchondral bone.